KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Short term Debt (2016 - 2025)

Thermo Fisher Scientific's Short term Debt history spans 17 years, with the latest figure at $3.5 billion for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt rose 59.58% year-over-year to $3.5 billion, compared with a TTM value of $3.5 billion through Dec 2025, up 59.58%, and an annual FY2025 reading of $3.5 billion, up 59.58% over the prior year.
  • Short term Debt for Q4 2025 was $3.5 billion at Thermo Fisher Scientific, down from $3.8 billion in the prior quarter.
  • The five-year high for Short term Debt was $6.1 billion in Q2 2023, with the low at $4.0 million in Q2 2021.
  • Average Short term Debt over 5 years is $3.0 billion, with a median of $3.2 billion recorded in 2025.
  • Year-over-year, Short term Debt plummeted 99.46% in 2021 and then soared 46550.0% in 2022.
  • Tracing TMO's Short term Debt over 5 years: stood at $2.5 billion in 2021, then soared by 119.91% to $5.6 billion in 2022, then plummeted by 35.31% to $3.6 billion in 2023, then tumbled by 38.65% to $2.2 billion in 2024, then surged by 59.58% to $3.5 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Short term Debt are $3.5 billion (Q4 2025), $3.8 billion (Q3 2025), and $2.2 billion (Q2 2025).